This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

LifeMap Sciences, A Subsidiary Of BioTime, Announces Release Of GeneCards® Version 3.11

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of GeneCards ®, Version 3.11. The new release is available at www.genecards.org. GeneCards ® is a comprehensive online database that provides comprehensive information on all human genes. It is accessed by professionals in many institutions including academia, research hospitals, patent offices, and leading biotech and pharma companies. LifeMap Sciences holds the exclusive worldwide license to market GeneCards ® from Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science.

GeneCards ® 3.11 now showcases gene-related scientific conferences, including links to ESCMID 2014 on Microbiology & Infectious Diseases, AD/PD 2014 on Alzheimer’s and Parkinson’s disease and ISPPD-9 on Pneumococci and Pneumococcal diseases.

Additional features of the new GeneCards ® release include:

  • More than 122,000 gene entries, including the world’s largest arsenal of ~77,000 non-protein-coding RNAs.
  • Revamped comprehensive version of the popular disease-gene list with links to MalaCards ( www.malacards.org), our Human Disease Compendium.
  • Enhanced information about genetic variations and disease mutations from UniProtKB
  • Gene classifications from HGNC and IUPHAR
  • Information on protein-binding ligands from the International Union of Basic and Clinical Pharmacology (IUPHAR)
  • Enhanced proteomics section with new tissue expression data from the renown MAXQB
  • Improved presentation of expression in embryonic tissues from LifeMap Discovery™ ( discovery.lifemapsc.com) and new antibodies.

“It is a pleasure to see GeneCards making new progress in its mission to cover ‘all about human genes’. I am especially proud to see the new information from the International Union of Basic and Clinical Pharmacology, covering both gene-related binding molecules (ligands) and protein classification. Along with our newly enhanced super-pathways and novel proteome data, these items portray the inventiveness of our academic team,” said Professor Doron Lancet, Ph.D., The Ralph D. and Lois R. Silver Professor of Human Genomics, at the Weizmann Institute of Science.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs